Something I don't computeAchieving a positive adjusted EBITDA, while burdeining the payroll by adding some experts to the oncology program, is something I cannot compute. Unless they expect a very increase in the legacy drugs in terms of revenue and gross margin Those experts are hired to assess and rethink the whole approach starting form the dosing, to the chosing of the right profiles of the patients to be enrolled in the testing, to the gating processes. They will be a charge to TH.for a long period of time. Hence, I do not expect a positive adjusted EBITDA by the end of 2023 unless a miracle happens in the selling of the legacy dugs.